cancer patients – Oral Cancer News

Cancer patients who use alternative medicine more than twice as likely to die

Source: http://www.independent.co.uk/ Date: August 15, 2017 After five years, 78.3 per cent of people who opted for medical treatment were still alive compared to just 54.7 percent of people who opted for alternative therapies. A new study has shown that cancer sufferers who turn to alternative therapies in preference to conventional medicine are more than twice as likely to die. Scientists from America's prestigious Yale University found that patients were more likely to be cured through conventional medicine, despite anecdotal evidence from some who say their cancer was cured by turning to natural or alternative remedies, . Researchers sifted through the National Cancer Database for their study “Use of Alternative Medicine for Cancer and its Impact on Survival”. They tracked 280 people who were diagnosed with the disease in 2004 and opted for alternative medicine and 560 “control” cancer patients who underwent conventional treatments such as chemotherapy, radiotherapy and surgery. After five years, 78.3 per cent of people who opted for medical treatment were still alive compared to just 54.7 percent of people who opted for alternative therapies. The study also looked at different types of cancer including breast, lung, prostate and colorectal. They found those with lung cancer were twice as likely to die after five years if they had opted for alternative therapies. Breast cancer patients who used alternative therapies were five times as likely to have lost their lives to the disease.Colorectal cancer patients were four times more likely to die if they rejected conventional medicine in favour of alternative [...]

Charlotte Parker2017-08-15T13:32:27-07:00August, 2017|Oral Cancer News|

Cancer patients sometimes can’t get coverage at the hospitals they want

Source: Washington Post Author: Michelle Andrews Published: January 15 Getting cancer is scary. Discovering that your health plan doesn’t give you access to leading cancer centers may make the diagnosis even more daunting. As insurers participating in the health marketplace shrink their provider networks and slash the number of plans that offer out-of-network coverage, some consumers with cancer are learning that their treatment options can sometimes be limited. One reader wrote to Kaiser Health News last month saying that she was dismayed to learn that none of the plans offered on the New York marketplace provides access to Memorial Sloan Kettering Cancer Center in New York, where she is a patient. Memorial Sloan Kettering is a well-regarded cancer center that is affiliated with the National Comprehensive Cancer Network and the National Cancer Institute.It participates in New York’s Essential Plan, which is available to lower-income people but not to people enrolling in plans with the familiar categories of bronze, silver, gold and platinum. NCCN is an alliance of 27 cancer centers whose physicians and researchers develop clinical practice guidelines that are widely respected. The National Cancer Institute’s 69 designated cancer centers, which are recognized for their scientific leadership and research, can offer patients access to cutting-edge treatments and clinical trials. A 2015 survey found that three-quarters of NCI-designated cancer centers said they participated in at least some exchange plans, and 13 percent said they were included in all exchange plans in their state. Among centers that didn’t participate in any exchanges, [...]

Charlotte Parker2017-01-17T10:48:53-07:00January, 2017|Oral Cancer News|

Antioxidants May Cause More Harm Than Good in Cancer Patients

Source: medscape.comAuthor: Zosia Chustecka While alternative health gurus often encourage increasing antioxidants in the diet and the taking of antioxidant nutritional supplements such as beta-carotene, vitamins A, C, and E, and selenium, new research findings suggest that antioxidants could do more harm than good, especially in cancer patients. The idea is discussed in a perspective article on the promise and perils of antioxidants for cancer patients in the July 10 issue of the New England Journal of Medicine. Coauthor David Tuveson, MD, PhD, professor and deputy director of the Cold Spring Harbor Laboratory Cancer Center in New York, explained in an interview with Medscape Medical News that the idea that antioxidants could be useful in cancer goes back to Linus Pauling, and is based on observations that oxidation within cells is needed for cell growth. "As cancer cells growth rapidly, a cancer cell would have more oxidation within it than a normal cell," he added, and the hope was that antioxidants would interfere with these cellular oxidative processes and would suppress the growth. "Although some early preclinical studies supported this concept," the authors write, there have now been several clinical trials that have shown no effect of antioxidants on reducing the incidence of cancer, and there have even been suggestions of harm in persons who are at risk for cancer. Dr. Tuveson noted a clinical trial from Scandinavia in the early 1990s, which found that high doses of antioxidants, particularly beta-carotene, were associated with more lung cancer rather than less as had been hoped for. There was [...]

Charlotte Parker2014-07-14T15:04:19-07:00July, 2014|Oral Cancer News|

ASCO Launches New Survivorship Guidelines

Author: Roxanne NelsonSource: medscape.com The American Society of Clinical Oncology (ASCO) has issued 3 new evidence-based clinical practice guidelines on the prevention and management of common symptoms that affect a large number of cancer survivors — neuropathy, fatigue, and depression and anxiety. The number of cancer survivors in the United States has risen exponentially, from 3.0 million in 1971 to about 13.7 million currently. That is good news, but the downside is that survivors often face long-term health issues related to their disease and treatment. Thus, there is an outstanding need for comprehensive guidance to assist clinicians in this management process. The ASCO recommendations reinforce the fact that both physical and psychological needs have to be addressed in this population. The guidelines, published online April 14 in the Journal of Clinical Oncology, are the first in a series that will focus on survivorship care. Peripheral Neuropathy Chemotherapy-induced peripheral neuropathy (CIPN) is a common treatment-related adverse event and can affect a patient's long-term quality of life. It is estimated that about 38% of patients who are treated with multiple agents develop CIPN, but this can vary, depending on the actual regimen and duration of treatment. Chemotherapy combinations associated with a higher incidence of CIPN are those that involve platinum drugs, vinca alkaloids, bortezomib, and/or taxanes. Symptoms vary, and range from numbness and tingling to shooting pain in the arms and legs. If symptoms are really severe, dose reduction or another regimen might be necessary. For a minority of patients, severe symptoms can last for years. [...]

Charlotte Parker2014-04-30T12:32:48-07:00April, 2014|Oral Cancer News|

Cancer clinics are turning away thousands of Medicare patients. Blame the sequester.

Posted by Sarah Kliff on April 3, 2013 at 5:46 pmhttp://www.washingtonpost.com Ralph V. Boccia of the Center for Cancer and Blood Disorders runs a cancer clinic that is in danger of losing funding due to the sequester cuts. (Sarah L. Voisin/The Washington Post) Cancer clinics across the country have begun turning away thousands of Medicare patients, blaming the sequester budget cuts. Oncologists say the reduced funding, which took effect for Medicare on April 1, makes it impossible to administer expensive chemotherapy drugs while staying afloat financially. Patients at these clinics would need to seek treatment elsewhere, such as at hospitals that might not have the capacity to accommodate them. “If we treated the patients receiving the most expensive drugs, we’d be out of business in six months to a year,” said Jeff Vacirca, chief executive of North Shore Hematology Oncology Associates in New York. “The drugs we’re going to lose money on we’re not going to administer right now.” After an emergency meeting Tuesday, Vacirca’s clinics decided that they would no longer see one-third of their 16,000 Medicare patients. “A lot of us are in disbelief that this is happening,” he said. “It’s a choice between seeing these patients and staying in business.” Some who have been pushing the federal government to spend less on health care say this is not the right approach. “I don’t think there was an intention to disrupt care or move it into a more expensive setting,” said Cathy Schoen, senior vice president of the [...]

Charlotte Parker2013-04-05T13:41:32-07:00April, 2013|Oral Cancer News|

Oncologists Favor Psychosocial Care, But Give It Short Shrift

Source: Oncology STAT MIAMI (EGMN) - Oncologists endorse the idea of connecting cancer patients to psychosocial care at the conclusion of active treatment. But practice doesn't align with beliefs, perhaps because they are unfamiliar with where to refer their patients for care. Among 57 oncologists who responded to a survey in the southeastern United States, 35, or 61%, considered psychosocial care to be beneficial. A majority thought it was "important" following cancer treatment, reported Laurie Freeman-Gibb at the annual conference of the American Psychosocial Oncology Society (APOS). But the oncologists said they spent just 4.2 minutes, on average, discussing psychosocial care during consultations, according to Ms. Freeman-Gibb, a lecturer in the department of nursing at the University of Windsor in Ontario, and her colleague Andrew Hatchett, Ph.D., of the University of Louisiana at Lafayette's department of kinesiology. And since only about 1 in 6 oncologists responded to the survey - it was sent to 350 practitioners - the findings may present an overly optimistic picture of what happens in real-life practice when a patient leaves active treatment and returns to the community for care. "I think it's sometimes a time constraint," said Ms. Freeman-Gibb. "If you only have 20 minutes to see this person and you open the floodgates to what's really going on, you might never get out the door ... especially if you don't know whom to tell the patient to call." Dr. Hatchett said the impetus for the study was a series of conversations he had with [...]

Charlotte Parker2012-05-02T10:45:02-07:00May, 2012|Oral Cancer News|

Cancer Patients Who Smoke Report Worse Pain, Symptoms

Source: MedScapeToday.com February 24, 2012 (Palm Springs, California) — Cancer patients who smoke experience more severe symptoms than nonsmoking cancer patients and are also at greater risk of misusing opioids, a new study shows. "Our findings show a profile of higher levels of physical symptoms (pain, fatigue, poor appetite, and insomnia) and psychological symptoms (depression and anxiety) among smokers than non-smokers," report Diane Novy, PhD, from the Pain Management Center at the University of Texas MD Anderson Cancer Center in Houston, Texas, and colleagues. The findings underscore the importance of smoking cessation for this patient population, she told Medscape Medical News, even though it's unclear if there is a causal effect. "We don't know the cause. They may smoke more because of the pain," she said in an interview. However, studies also show that smoking has been known to increase certain types of pain such as back pain, and nerve pain, she added. "If we can motivate them to stop smoking, I think they're better off." The findings were presented here at the American Academy of Pain Medicine (AAPM) 28th Annual Meeting. Pain, Fatigue, Insomnia The study included 486 cancer patients (52% female), with a mean age of 55 years, who were referred to the Pain Management Center for uncontrolled pain. Ninety-four patients were smokers, and the rest (n = 356), classified as nonsmokers, were former smokers or never-smokers. The patients were diagnosed with a wide range of cancers, the most common being gastrointestinal (18.5%), followed by hematologic (15%) and [...]

Charlotte Parker2012-02-28T17:43:34-07:00February, 2012|Oral Cancer News|

New Study for Cancer Patients to Help Improve the Body’s Ability to Fight Illness

Source: Sign On San Diego A Santa Monica research center will test an experimental therapeutic filtering device being developed by Aethlon Medical on blood taken from cancer patients, the San Diego company said Wednesday. The study will target exosomes, bubbles of protein and RNA molecules excreted by cancerous cells that can block immune system cells from fighting the illness. By removing exosomes from circulating blood, Aethlon officials hope their device will improve the body's ability to fight cancer and the effectiveness of treatments such as chemotherapy. Blood taken from 25 patients with non-small cell lung cancer, prostate cancer, melanoma, sarcoma, and head and neck cancer will be circulated through the Hemopurifier device. In clinical use, blood would be filltered directly from the patient and returned to the body in a similar way to kidney dialysis. However, in the newly announced pre-clinical trial blood will not be returned to patients, Aethlon Chairman and Chief Executive Officer James Joyce said. "If we validate that our Hemopurifier is efficient in capturing exosomes, its possible that we could transition towards a human treatment study to evaluate exosome clearance from the entire circulatory system," he said. The test will be conducted by the Sarcoma Oncology Center, a nonprofit independent research institute focused on cancer therapy development. "This clinical histological study is a critical validation step in Aethlon's Hemopurifier strategy for cancer," said Dr. Sant Chawla, the trial's chief investigator. "The concept of 'subtractive therapy', eliminating a major mechanism of tumor progression and resistance to drugs, [...]

Oral Cancer Foundation News Team - A2011-08-25T09:51:41-07:00August, 2011|Oral Cancer News|

High risk of developing ONJ for cancer patients on bisphosphonates

Source: Dr.Bicuspid.com Research has shown that cancer patients on bisphosphonates are at risk of developing osteonecrosis of the jaw (ONJ) and that those on the intravenous form of the drug are at a higher risk compared with those on the oral drugs. However, a new study that looked at cancer patients on zoledronic acid (ZOL) and chemotherapy combined with the antiangiogenic agent bevacizumab (BEV) who underwent a dental exam before starting treatment found that none of them developed ONJ (JADA, May 2011, Vol. 142:5, pp. 506-513). Researchers from the University of Siena in Italy investigated the incidence of and risk factors for ONJ in patients with metastases to the bone from solid tumors who received ZOL and BEV. Their study included 59 patients (34 with breast cancer and 25 with non-small cell lung cancer [NSCL]) who received 4 mg of ZOL intravenously every four weeks and 15 mg per kg of BEV every three weeks. The median time the participants received ZOL therapy was 18 months, while the median time participants received BEV therapy was 16 months. The researchers took several measures to reduce the study participants' risk of developing ONJ, including the following: Dental caries and periodontal disease were treated before starting study treatment. Mouth rinses with chlorhexidine and local antibiotic agents were administered before baseline oral hygiene. Recommendations were made for maintaining good oral hygiene. Teeth were extracted at least four weeks before starting ZOL and BEV therapy. Invasive dental procedures were avoided during treatment. If invasive dental [...]

Oral Cancer Foundation News Team - A2011-05-24T10:21:55-07:00May, 2011|Oral Cancer News|

Yale School of Medicine Researchers take a closer look at “smart drugs”

Source: Yale University Some of the most effective and expensive cancer drugs, dubbed "smart drugs" for their ability to stop tumors by targeting key drivers of cancer cell growth, are not effective in some patients. In two related studies, Yale School of Medicine researchers examined one such driver, the EGF receptor (EGFR), and found that a decoy receptor might be limiting the amount of drug that gets to the intended target. "We know that smart drugs like Cetuximab are not always effective in the cancer cells they're supposed to target because there are no positive predictive markers for selecting the patients who will benefit from treatment with EGFR-targeted therapies, including EGFR itself," said lead author Nita Maihle, professor in the Departments of Obstetrics, Gynecology & Reproductive Sciences and of Pathology at Yale School of Medicine. "Why would a patient be given an expensive drug if it doesn't work? Our studies provide new insight into this paradoxical EGFR testing conundrum." In a study published recently in the journal Cancer, Maihle and her team isolated a protein from human blood that looks like EGFR, but is actually a closely related variant called serum sEGFR. They showed that Cetuximab binds equally as well to serum sEGFR as it does to the intended EGFR cancer target. Those study results showed that sEGFR might act as a decoy receptor in the blood of cancer patients, tying up Cetuximab and therefore limiting the amount of Cetuximab that actually gets to the intended target. Such limitations may, [...]

Oral Cancer Foundation News Team - A2011-05-19T13:43:34-07:00May, 2011|Oral Cancer News|